Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
نویسندگان
چکیده
Author details Yale Cancer Center, 333 Cedar St, TMP 3, PO Box 208028, New Haven, CT 06520-8028, USA. Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia. Moffitt Cancer Center, Tampa, FL, USA. Veristat, LLC, Southborough, MA, USA. Hospices Civils de Lyon, Lyon, France.
منابع مشابه
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
BACKGROUND Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing treatment in patients with the best response of stable disease (SD). Histone deacetylase inhibitors are a novel class of drugs with activity in T cell malignancies. Romideps...
متن کاملResponses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a ...
متن کاملRomidepsin for the Treatment of Peripheral T-Cell Lymphoma
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomasassociatedwithpoorprognosis inmost subtypes. Diagnosis of this rare disease by expert hematopathologists improves accuracy of subtyping, and referral to academicorspecialtycenters is recommended.Manypatients, however, will receive treatment in the community, and knowledgeofapprovedagents is key tooptimizing thera...
متن کاملRomidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
BACKGROUND Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received ≥ 1 prior systemic therapy and patients with peripheral T-cell lymphoma (PTCL) who have received ≥ 1 prior therapy. Approval for PTCL was based on results (n...
متن کاملA phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
BACKGROUND There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %. METHODS A multicenter prospective phase II trial was conducted to investigate the role of the combination of gemcitabine plus romidepsin (GEMRO regimen) in rel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 10 شماره
صفحات -
تاریخ انتشار 2017